Search results
Results from the WOW.Com Content Network
All squamous cell carcinoma lesions are thought to begin via the repeated, uncontrolled division of cancer stem cells of epithelial lineage or characteristics. Accumulation of these cancer cells causes a microscopic focus of abnormal cells that are, at least initially, locally confined within the specific tissue in which the progenitor cell resided.
Typical symptoms of dry eye syndrome are dryness, burning [13] and a sandy-gritty eye irritation that gets worse as the day goes on. [14] Symptoms may also be described as itchy, stinging or tired eyes. [13] [15] Other symptoms are pain, redness, a pulling sensation, and pressure behind the eye.
Optic nerve melanocytoma does not usually produce symptoms or grow. If they slowly grow, optic nerve melanocytoma can produce afferent pupillary defects (30%), subretinal fluid (10%), and an enlarged blind spot (75%). On fundoscopic exam, the optic disc may be swollen, atrophic, or even normal. [1] Central retinal vein occlusion may occur.
A major risk factor for AIR is a history of cancer, especially in paraneoplastic autoimmune retinopathy, where the autoimmune response is triggered by cancerous cells and cancer treatments. Cancer-associated retinopathy is commonly linked with cancers such as lung cancer and breast cancer, which trigger an autoimmune response due to malignant ...
Orbital lymphoma is a common type of non-Hodgkin lymphoma that occurs near or on the eye. Common symptoms include decreased vision and uveitis . Orbital lymphoma can be diagnosed via a biopsy of the eye and is usually treated with radiotherapy or in combination with chemotherapy .
Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye secondarily from a metastasis from a non-ocular tumor or may arise within the eye primarily (primary intraocular lymphoma, PIOL). PIOL is a subset of primary central nervous system lymphoma (PCNSL).
The treatment is one of three antibody-drug conjugates (ADCs) included in Merck's up to $22-billion joint development and commercialization deal with Daiichi Sankyo, signed last year.
Uveal melanoma is a type of eye cancer in the uvea of the eye. [4] It is traditionally classed as originating in the iris, choroid, and ciliary body, but can also be divided into class I (low metastatic risk) and class II (high metastatic risk). [4] Symptoms include blurred vision, loss of vision, and photopsia, but there may be no symptoms. [5]